A Phase 1, Randomized, Placebo-and Positive-Controlled Crossover Study to Determine the Effect of Single-Dose GC4419 on QTc Interval in Healthy Volunteers

NCT03164109 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers
Healthy

Interventions

DRUG: GC4419 IV
DRUG: Placebo
DRUG: Oral moxifloxacin

Sponsor

Galera Therapeutics, Inc.

Collaborators

[object Object]